Cost-effectiveness of novel diagnostic tools for idiopathic pulmonary fibrosis in the United States
Novel tools for diagnosing IPF reduced diagnostic costs, while overall incremental cost-effectiveness ratios were high due to treatment costs. New IPF diagnosis approaches may become more favourable with lower-cost treatments for IPF.
Authors
- Joshua Reicher (ORCID: https://orcid.org/0000-0002-8223-2264)
- David W. Hutton (ORCID: https://orcid.org/0000-0001-9677-1632)
- Michael Muelly (ORCID: https://orcid.org/0000-0002-3405-9671)
- Christopher J. Cadham (ORCID: https://orcid.org/0000-0001-9531-2733)
Institutions
- University of Michigan (US)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1186/s12913-025-12506-1
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00